Page 1 of 7
`
`www.medscape.com
`
`2011 Top Game Changers in Oncology
`Bruce D. Cheson, MD, David J. Kerr, MD, Mark G. Kris, MD, Maurie Markman, MD, John L. Marshall, MD, Kathy D. Miller,
`November 23, 2011
`MD, Nancy R. Terry
`Counting Down: Game Changers 10 Through 6
`In 2011, great progress was made in the science and management of a variety of cancers. Our Medscape
`commentators selected and ranked the top 10 game changers in oncology for 2011. Here are their selections.
`
`10. New Regimen Improves Outcomes in Neuroblastoma
`A provocative European study[1] showed improved outcomes in high-risk neuroblastoma using a high-dose
`myeloablative regimen. Until now, the best outcome in neuroblastoma has hovered around the 50% survival
`threshold, but the new regimen tested has pushed this up to 60%. European investigators say this regimen should
`be the new standard of care. "This is an incredible success and a great achievement for pediatric oncology," said
`Julie Park, MD, from Seattle Children's Hospital in Washington, who acted as discussant for the study.
`
`The results are important for patients with this extremely difficult-to-treat disease," said principal investigator Ruth
`Ladenstein, MD, MBA, Associate Professor of Pediatrics at the University of Vienna, Austria.
`
`Treatment for neuroblastoma comprises several steps. It begins with intense upfront chemotherapy to induce
`remission (induction) and is followed by surgery and radiation, myeloablative therapy with stem cell transplantation,
`and then consolidation therapy with 13-cis-retinoic acid and immunotherapy, if available.
`
`The European trial used an induction regimen known as rapid COJEC, which consists of both cisplatin and
`carboplatin, and then compared a high-dose myeloablative regimen known as BuMel (busulphan plus melphalan)
`with carboplatin, etoposide, and melphalan (control group).
`
`The BuMel group led to significantly improved survival at 3 years compared with the control group (60% vs 48%).
`"The superiority was based on a lower relapse rate," noted Dr. Ladenstein.
`
`Read the complete Medscape News article on this trial, which was presented during the plenary sessions of the
`2011 American Society for Clinical Oncology (ASCO®) annual meeting.
`
`9. A Shooting Gallery of Targets in Lung Cancer
`
`The treatment of non-small cell lung cancer (NSCLC) is undergoing a revolution driven by a greater understanding
`of the genetic factors fueling this disease. In personalized therapy, drugs are chosen according to the mutations
`found in the patient's tumor rather than chemotherapy chosen for the organ where the tumor is located.
`
`Contributing to the growing knowledge of genetic targets is a landmark study by the Lung Cancer Mutation
`Consortium (LCMC),[2] which involves 14 centers across the United States. The LCMC conducted a prospective
`study in which lung cancer tissue was assessed using a multiplex assay that identified 10 known driver mutations. In
`addition to EGFR and ALK, they are testing for KRAS, HER2, BRAF, PIK3CA, AKTI, MEKI, NRAS, and MET. Many
`of these mutations have targeted agents under development or, in the case of HER2, have targeted drugs already
`on the market (trastuzumab and lapatinib, which are used in breast cancer). The results so far show that 54% of the
`tested tumor samples have single-driver mutations. This information is now being used to select patients for first-line
`therapy with erlotinib or to place these patients into clinical trials with experimental targeted therapies specifically
`directed at their tumor mutation.
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 2 of 7
`
`"Although an individual driver mutation may have a single-digit percentage incidence, when you look at all of the
`possible mutations that exist in lung cancer, you are likely to find a mutation," said Mark G. Kris, MD, lead author
`and Chief of Thoracic Oncology at Memorial Sloan-Kettering Cancer Center in New York City, in a Medscape
`commentary. "Even in individuals who did not have a mutation that would suggest a certain clinical trial, we knew
`what treatments not to give those patients." This study, Dr. Kris added, "brings us one step closer to our goal of
`personalized medicine."
`
`View the complete commentary by Mark G. Kris, MD, and read the original Medscape News story on this trial, which
`was reported at the 2011 ASCO® annual meeting.
`
`8. Strongest Data Ever for ER-Positive Breast Cancer
`
`The combination of everolimus plus exemestane produced "the strongest data ever seen in estrogen receptor [ER]
`-positive breast cancer," principal investigator José Baselga, MD, from the Massachusetts General Hospital and
`Harvard Medical School, Boston, told Medscape Medical News. The pivotal phase 3 study, known as BOLERO-2,[3]
`was stopped early because of the benefit observed. Results were unveiled at the 2011 European Multidisciplinary
`Cancer Congress (EMCC).
`
`"Everolimus is the most important advance in breast cancer since trastuzumab," said Fabrice André, MD, PhD, from
`the Institut Gustave Roussy, Paris, France, who acted as discussant. "The data are robust and are clinically
`relevant," he said, adding that "the efficacy is in the range of the most important recent advances in the field of
`medical oncology."
`
`Everolimus is an mTOR inhibitor that has already been approved in the United States for the treatment of
`progressive neuroendocrine tumors of pancreatic origin and advanced renal cell carcinoma in certain patients.
`Exemestane is an aromatase inhibitor that is already widely used as adjuvant therapy for ER-positive breast cancer.
`Both drugs are taken orally.
`
`Read the complete Medscape News story on this trial.
`
`7. Extended Adjuvant Treatment Improves Survival in GIST
`
`Extended adjuvant treatment with imatinib improves survival in patients with high-risk gastrointestinal stromal tumors
`(GIST). Imatinib administered for 3 years improved both relapse-free survival and overall survival in patients after
`surgery, compared with 1 year of adjuvant treatment.[4]
`
`Previous data showed that initiating adjuvant imatinib therapy reduces the risk for GIST recurrence compared with
`placebo. "But the effect of imatinib on overall survival is not known," said lead author Heikki Joensuu, MD, Professor
`of Oncology at Helsinki University Central Hospital in Finland, who presented the findings during the plenary session
`here at the ASCO® 2011 annual meeting.
`
`The 5-year relapse-free survival in patients was higher in those who received 3 years of treatment than in those who
`received 1 year (65.6% vs 47.9%; hazard ratio [HR], 0.46; P < .0001). The 5-year overall survival was also better in
`patients who received 3 years of therapy (92.0% vs 81.7%; HR. 0.45; P = .019).
`
`Kathy Miller, MD, Chair of the scientific program for the 2011 ASCO® annual meeting, said in a Medscape
`commentary, "There had been a lot of debate in the GIST community that perhaps the drug was so effective in
`people with metastatic disease that you didn't really need to give adjuvant therapy for a longer time or maybe you
`didn't need to give it at all. You could just catch up and treat these folks when they recurred, and that was definitely
`not true. A longer duration of therapy, 3 years instead of 1, improved survival."
`
`"We are looking at 92% in the 3-year group, and that is very high," said Dr. Joensuu. "We are making substantial
`improvement here."
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 3 of 7
`
`View the complete commentary by Kathy D. Miller, MD, and read the original Medscape News story on this trial.
`
`6. New Hope for Patients With Refractory Lymphoma
`
`The experimental agent brentuximab vedotin, which has shown strong responses in patients with resistant and
`refractory Hodgkin lymphoma, was the first drug approved for lymphoma in 30 years. The results were reported at
`the 52nd annual meeting of the American Society of Hematology by Robert Chen, MD, Assistant Professor at the
`City of Hope National Medical Center in Duarte, California.[5] The data come from a single-group multicenter study of
`102 patients, all of whom had failed autologous stem cell transplantation and a median of 4 chemotherapy regimens
`(range, 1-13). The median age of patients was 31 years (range, 15-77 years).
`
`Brentuximab 1.8 mg/kg was administered as a 30-minute outpatient intravenous infusion once every 3 weeks for up
`to 16 cycles of therapy (median, 9 cycles).
`
`Responses were "dramatic," Dr. Chen said. The objective response rate was 75%, and tumor reduction was
`demonstrated in 94 patients (96%). Around one third of patients (34%) achieved complete remission.
`
`In August, the US Food and Drug Administration (FDA) granted accelerated approval of brentuximab vedotin
`infusion for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma,
`as reported at the time by Medscape.
`
`"Why are we so excited about this?" asked Bruce D. Cheson, MD, Professor of Medicine, Georgetown University,
`Washington, DC, in a Medscape commentary. "Not only is this a great drug, it is also a proof of concept. We now
`have demonstrated that you can take an antibody and link it strongly to a poison. It will get in the cells and kill them,
`without doing much damage to the rest of the body. This will be one of many to follow in its footsteps."
`
`View the complete commentary from Bruce D. Cheson, MD, and read the original Medscape News story.
`
`5. Improved Survival in Metastatic Pancreatic Cancer
`A chemotherapy combination provided the best survival time ever reported in metastatic pancreatic cancer,
`according to a study from French researchers, but the combination of 5-fluorouracil, leucovorin, irinotecan, and
`oxaliplatin (FOLFIRINOX) was considerably more toxic than gemcitabine. Data from the study, which were first
`presented at the 2010 annual meeting of ASCO® and reported by Medscape Medical News at that time, were
`published in May in The New England Journal of Medicine.[6] Although the data are largely the same, the published
`paper includes new information on quality-of-life measures, said lead author Thierry Conroy, MD, from the Centre
`Alexis Vautrin, Vandoeurve les Nancy, France.
`
`Gemcitabine, used alone or in combination with other agents, has been the "reference regimen" for advanced
`pancreatic cancer treatment for an extended period of time, according to Dr. Conroy and colleagues from 48 centers
`in France. However, the study authors propose that FOLFIRINOX is now a first-line option for patients with
`metastatic pancreatic cancer "who are younger than 76 years, and who have a good performance status (Eastern
`Cooperative Oncology Group score [ECOG] 0 or 1), no cardiac ischemia, and normal or nearly normal bilirubin
`levels."
`
`"This is the first study to show substantial improvements in survival in advanced pancreatic cancer," said Alok A.
`Khorana, MD, Associate Professor and Vice-Chief of Hematology-Oncology at the University of Rochester,
`Rochester, New York, in a Medscape viewpoint. "It is unfortunate, however, that this gain occurs with an aggressive
`multichemotherapy regimen rather than with the addition of targeted therapy as many had hoped for. Although the
`efficacy of the regimen is clear and substantial, concerns about toxicity and tolerability are ongoing."
`
`Read the complete Medscape News story on this paper and the complete viewpoint by Alok A. Khorana, MD.
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 4 of 7
`
`4. New Standard of Care for High-Risk ALL
`A regimen of high-dose methotrexate was found to be superior to the standard protocol of escalating methotrexate
`in children and young adults with high-risk B-precursor acute lymphoblastic leukemia. The results of a phase 3 trial,
`[7] which were presented at the 2011 ASCO® annual meeting, established a new standard of treatment for this
`population.
`
`In a planned interim analysis, 5-year event-free survival for patients who received the high-dose regimen was 82%
`compared with 75% for those receiving the escalation protocol.
`
`"We feel that it is the standard of care to receive high-dose methotrexate in this population," said lead author Eric C.
`Larsen, MD, Director of the Maine Children's Cancer Program and the division of pediatric hematology/oncology at
`the Barbara Bush Children's Hospital at Maine Medical Center in Portland, adding that "high-dose methotrexate will
`be incorporated in current and future Children's Oncology Group trials for children and young adults."
`
`Read the complete Medscape News story on this paper.
`
`3. Increased Survival in Metastatic HER2-Positive Breast Cancer
`The first randomized trial to compare the novel agent trastuzumab emtansine (T-DM1) with standard therapy shows
`that it significantly increased progression-free survival in women with metastatic breast cancer.[8] The study was
`presented at the 2011 EMCC in Stockholm, Sweden.
`
`"First-line treatment with T-DM1 was associated with a statistically significant improvement in progression-free
`survival and was also associated with a reduction in the risk for toxicity," said lead author Sara Hurvitz, MD, Director
`of the Breast Oncology Program, Division of Hematology/Oncology, University of California, Los Angeles.
`
`Median progression-free survival was 14.2 months for women who received T-DM1 and 9.2 months for those who
`received standard therapy with trastuzumab plus docetaxel. The hazard ratio was 0.59, indicating that treatment with
`T-DM1 reduced the probability of disease progression or death by 41% compared with standard therapy, noted Dr.
`Hurvitz.
`
`"These results validate the hypothesis that the unique targeted delivery of chemotherapy through T-DM1 may lead
`to an improved therapeutic index," she said.
`
`Fabrice André, MD, PhD, Associate Professor at the Institut Gustave Roussy, Villejuif, France, as reported in a
`Medscape commentary, finds T-DM1 interesting for 3 distinct reasons. "The first is conceptual -- This is the first time
`that an immunoconjugate (a combination of a monoclonal antibody and a cytotoxic agent) has shown efficacy in
`cancer. It's a new concept, and we have the proof of concept. The second reason is the finding that
`immunoconjugate is safer compared with conventional chemotherapy. We had the presentation today, during which
`we heard that the frequency of grade 3 adverse events was lower in patients treated with T-DM1. The third reason it
`is so important is that these drugs can be delivered for a long time. Because of this prolongation of the treatment, we
`had a better progression-free survival, specifically in HER2-positive breast cancer."
`
`Because T-DM1 is not toxic, it can be administered for a long period of time, which leads to long-term progression-
`free survival.
`
`"We are entering in a new era with this trial," said Dr. André. "At the very beginning, to obtain a response the drug is
`not better. Once we have a response and once the drug is working, we can administer the drug for a longer time
`period and know that the patient is not going to present with progressive disease, but at the opposite end -- in
`patients treated with trastuzumab and docetaxel -- we have to stop both the chemotherapy agents. Then the patient
`is going to have a progressive disease. In terms of induction of the response, there is not any major difference
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 5 of 7
`
`between T-DM1 and a combination of trastuzumab and docetaxel, but then duration of the response is very long.
`We are going through a scenario where we have induction with T-DM1, and once the patient has a response, then
`the response can be long lasting."
`
`View the complete commentary from Fabrice André, MD, PhD, and read the original Medscape News story on this
`trial.
`
`2. Lung Cancer Screening Comes of Age
`The landmark National Lung Screening Trial,[9] which enrolled 53,000 persons,showed that screening with low-dose
`spiral CT reduced mortality from lung cancer by 20%. CT screening was compared with chest radiographs, which
`have not shown any mortality reduction in previous trials.
`
`The study was accompanied by expressions of enthusiasm from the American oncology community. "It's gratifying.
`We've been looking for this kind of good news in lung cancer for a long time," Otis Brawley, MD, Chief Medical
`Officer at the American Cancer Society, told Medscape Medical News. "It's simply an amazing result with an
`immediate impact on this disease," Mark G. Kris, MD, Chief of Thoracic Oncology at Memorial Sloan-Kettering
`Cancer Center, reported in a Medscape commentary.
`
`"Finally we have a screening test that meets that gold standard and has a substantial opportunity to decrease the
`death rate for lung cancer," said Dr. Kris. "In the group that was screened, all patients had smoked 30 pack-years,
`which is the equivalent of 1 pack per day for 30 years, 2 packs per day for 15 years, and so on. Based on these
`data, it makes sense to recommend screening with a low-dose helical CT for any person who has smoked 30 pack-
`years."
`
`In November, the National Comprehensive Cancer Network in an updated set of guidelines came out in favor of lung
`cancer screening, recommending the use of low-dose CT screening for select patients at high risk for disease.
`
`View the complete commentary by Mark G. Kris, MD, and read the original Medscape News story on this trial.
`
`1. The Top Game Changer for 2011 in Oncology
`Unprecedented Advances in Melanoma
`
`In 2011, 2 studies and 2 drug approvals revolutionized therapy for patients with metastatic melanoma. Vemurafenib
`and ipilimumab quickly became household names after studies on their efficacies in metastatic melanoma were
`highlighted in the plenary session of the 2011 ASCO® annual meeting.
`
`Vemurafenib. In a phase 3 study[10] that was accompanied by much praise and grand declarations, the targeted
`therapy vemurafenib was shown to dramatically improve progression-free and overall survival, compared with
`standard chemotherapy, in patients with advanced melanoma with no previous treatment.
`
`Vemurafenib targets the V600E mutations in the BRAF gene, and an estimated 40%-60% of melanoma patients
`have this type of BRAF mutation.
`
`The progression-free survival data constitute "an unprecedented level of difference," said lead author Paul
`Chapman, MD, from Memorial Sloan-Kettering Cancer Center.
`
`This study is "practice changing," said Lynn Schuchter, MD, from the Abramson Cancer Center at the University of
`Pennsylvania in Philadelphia. Responses with the new oral therapy can be dramatic -- patients can have
`improvement within 72 hours of treatment, she said.
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 6 of 7
`
`In August, vemurafenib was approved by the FDA for the first-line treatment of both metastatic and unresectable
`melanomas, as reported at the time by Medscape News. The drug is specifically indicated for patients with
`melanoma whose tumors have V600E mutations in the BRAF gene.
`
`Ipilimumab. A phase 3, international, multicenter study showed ipilimumab, a human monoclonal antibody, to be
`effective as first-line therapy in both metastatic and unresectable melanoma.[11] The data on first-line use were
`presented at the 2011 ASCO® annual meeting and published online in The New England Journal of Medicine to
`coincide with the presentation.
`
`Ipilimumab in combination with dacarbazine improved overall survival in patients with previously untreated
`metastatic melanoma, compared with dacarbazine plus placebo, said senior author Jedd Wolchok, MD, from
`Memorial Sloan-Kettering Cancer Center. The drug was approved by the FDA as first-line therapy for patients with
`unresectable or metastatic melanoma, based on a study of previously treated patients. At the time of its approval,
`ipilimumab was the first agent ever proven to improve survival in advanced melanoma, as reported at the time by
`Medscape.
`
`Overall survival in the study was significantly longer in the ipilimumab group than in the placebo group (11.2 vs 9.1
`months; hazard ratio [HR] for death, 0.72; P < .001), Dr. Wolchok and his coauthors reported. The ipilimumab group
`had higher survival rates than the placebo group at 1 year (47.3% vs 36.3%), 2 years (28.5% vs 17.9%), and 3
`years (20.8% vs 12.2%). The 3-year results are "very mature," commented Dr. Wolchok.
`
`On the basis of this study, ipilimumab was approved by the FDA for first-line treatment of both metastatic and
`unresectable melanomas.
`
`"Today we are in the very fortunate position of having 2 medicines approved for metastatic melanoma, the first time
`in 13 years that any medicine has been approved by the FDA for melanoma," said Dr. Wolchok. "Importantly, both of
`these medicines were approved on the basis of the gold standard endpoint -- namely, improvement of overall
`survival. We believe these newly approved treatments are a source of great hope to patients, their families, and their
`physicians."
`
`View 2 complete commentaries by Jedd Wolchok, MD, and read the original Medscape News stories on
`vemurafenib and ipilimumab.
`
`References
`
`1. Ladenstein RL, Poetschger U, Luksch R, et al. Busulphan-melphalan as a myeloablative therapy (MAT) for
`high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. Program and abstracts of the American
`Society of Clinical Oncology Annual Meeting and Exposition; June 3-7, 2011, Chicago, Illinois. Abstract 2.
`
`2. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000
`patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Program and
`abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition; June 3-7, 2011,
`Chicago, Illinois. Abstract CRA7506.
`
`3. Baselga J, Campone M, Piccart-Gebhart J, et al. Everolimus in combination with exemestane for
`postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results
`of the BOLERO-2 phase III trial. Program and abstracts of the 2011 European Multidisciplinary Cancer
`Congress; September 23-27, 2011; Stockholm, Sweden. Abstract LBA9.
`
`4. Joensuu H, Eriksson M, Hartmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of
`operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). Program and
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 6
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Page 7 of 7
`
`abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition; June 3-7, 2011;
`Chicago, Illinois. Abstract LBA1.
`
`5. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35)
`in patients with relapsed or refractory Hodgkin lymphoma (HL). Program and abstracts of the American
`Society of Clinical Oncology Annual Meeting and Exposition; June 3-7, 2011; Chicago, Illinois. Abstract 8031.
`
`6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
`N Engl J Med. 2011;364:1817-1825. Abstract
`
`7. Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi
`methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute
`lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232. Program
`and abstracts of the American Society of Clinical Oncology; June 3-7, 2011, Chicago, Illinois. Abstract 3.
`
`8. Hurvitz S, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in
`previously untreated HER-2 positive metastatic breast cancer (MBC): primary results of a randomized,
`multicenter, open-label phase II study (TDM4450g/BO21976). Program and abstracts of the 2011 European
`Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 5001.
`
`9. Aberle C, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic
`screening. N Engl J Med. 2011;365:395-409. Abstract
`
`10. Chapman PB, Hauschild A, Robert C. Phase III randomized, open-label, multicenter trial (BRIM3) comparing
`BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.
`Program and abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition; June
`3-7, 2011; Chicago, Illinois. Abstract LBA4.
`
`11. Wolchok JD, Thomas L, Bondarenko IN. Phase III randomized study of ipilimumab (IPI) plus dacarbazine
`(DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
`Program and abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition; June
`3-7, 2011; Chicago, Illinois. Abstract LBA5.
`
`Medscape Oncology © 2011 WebMD, LLC
`
`Cite this article: Bruce D. Cheson, David J. Kerr, Mark G. Kris, et. al. 2011 Top Game Changers in
`Oncology. Medscape. Nov 23, 2011.
`
`http://www.medscape.com/viewarticle/754136_print
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 7
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`2011 Top Game Changers in Oncology
`
`Page 1 of 2
`
`Authors and Disclosures
`
`Author(s)
`
`Bruce D. Cheson, MD
`
`Professor of Medicine, Georgetown University; Head of Hematology, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC
`
`Disclosure: Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
`
`Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Cephalon, Inc.; Celgene Corporation; Millennium: The Takeda Oncology Company; Allos
`Therapeutics, Inc.; GlaxoSmithKline
`
`Professor, Nuffield Department of Clinical and Lab Sciences, University of Oxford; Honorable Consultant and Medical Oncologist, Oxford Radcliffe Hospitals Trust, Oxford, United Kingdom
`
`David J. Kerr, MD
`
`Disclosure: David J. Kerr, MD, has disclosed the following relevant financial relationships:
`
`Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Roche; AstraZeneca Pharmaceuticals, LP
`
`Served as a speaker or member of a speakers bureau for: Roche
`
`Received research grants from: Merck & Co., Inc.; GlaxoSmithKline; AstraZeneca Pharmaceuticals, LP; Genomic Health
`
`Received income in an amount equal to or greater than $250 from: AstraZeneca Pharmaceuticals, LP; Genomic Health; Roche
`
`Mark G. Kris, MD
`
`Chief, Thoracic Oncology, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College, New York, New York
`
`Disclosure: Mark G. Kris, MD, has disclosed the following relevant financial relationships:
`
`Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis
`
`Vice President, Patient Oncology Services; National Director for Medical Oncology, Cancer Treatment Centers of America, Philadelphia, Pennsylvania
`
`Maurie Markman, MD
`
`Disclosure: Maurie Markman, MD, has disclosed the following relevant financial relationships:
`
`Served as speaker or a member of a speakers bureau for: Eli Lilly and Company
`
`Received income in an amount equal to or greater than $250 from: Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Genentech, Inc.; Hana Biosciences, Inc.;
`Morphotech; sanofi-aventis
`
`Professor of Medicine; Chief, Division of Hematology-Oncology; Director, Clinical Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
`
`John L. Marshall, MD
`
`Disclosure: John L. Marshall, MD, has disclosed the following relevant financial relationships:
`
`Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen Inc.; Genentech, Inc.; Roche
`
`Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Genentech, Inc.; Roche
`
`Received research grants from: Amgen Inc.; Genentech, Inc.; Roche
`
`Received income in an amount equal to or greater than $250 from: Amgen Inc.; Genentech, Inc.; Roche
`
`Kathy D. Miller, MD
`
`Associate Professor of Medicine, Indiana University School of Medicine; Hematology/Oncology Staff Physician, Breast Oncology, Indiana University Simon Cancer Center,
`Indianapolis, Indiana
`
`Disclosure: Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
`
`Served as a speaker or member of a speakers bureau for: Genentech, Inc.; Roche
`
`Received income in an amount equal to or greater than $250 from: Genentech, Inc.
`
`Nancy Terry
`
`http://www.medscape.com/viewarticle/754136
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 8
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`2011 Top Game Changers in Oncology
`
`Page 2 of 2
`
`Editorial Director, Medscape, New York, New York
`
`Disclosure: Nancy Terry has disclosed no relevant financial relationships.
`
`http://www.medscape.com/viewarticle/754136
`
`7/30/2014
`
`IMMUNOGEN 2008, pg. 9
`Phigenix v. Immunogen
`IPR2014-00676
`
`